Wolf, J.M. et al. 2023. Adverse drug events, comorbidities, and older age are statistically more prevalent in COVID-19 hospitalized patients treated with remdesivir than tocilizumab in a private hospital from southern Brazil. Clinical and Biomedical Research. 43, 3 (nov. 2023). DOI:https://doi.org/10.22491/2357-9730.129384.